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Abstract 
Objective 
To examine the effect of medications with anticholinergic effects on cognitive 
impairment and deterioration in a cohort of people with Alzheimer’s Dementia (AD). 
Methods 
Cognitive function was measured at baseline and at 6 and 18 month follow-up using 
the Mini-Mental State Exam (MMSE), the Severe Impairment Battery (SIB) and the 
Alzheimer’s Disease Assessment Battery, Cognitive subsection (ADAS-COG) in a 
cohort study of 224 participants with Alzheimer’s Dementia (AD). Baseline 
anticholinergic Burden Score (ABS) was measured using the Anticholinergic Burden 
Scale and included all prescribed and over the counter medication. 
Results 
The average number of medications taken was 3.6 (SD 2.4) and the mean 
anticholinergic load was 1.1 (SD 1.4, range 0-7). The total number of drugs taken and 
anticholinergic load correlated (rho=0.44 p<0.01).  There were no differences in 
MMSE and other cognitive functioning at either 6 or 18 months after adjusting for 
baseline cognitive function, age, gender and use of cholinesterase inhibitors between 
those with, and those without high anticholinergenic load.  
Conclusions 
Medications with anticholinergic effect in patients with AD were not found to effect 
deterioration in cognition over the subsequent 18 months. Our study did not support a 
continuing effect of these medications on people with AD who are established on 
them.  
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Introduction 
There is increasing evidence that medications with anticholinergic effects may 
adversely affect cognitive function 1, 2. Older people are particularly sensitive to 
anticholinergic effects due to the significant age-related decrease in cholinergic 
neurons or receptors in the brain, the reduction in hepatic and renal clearance of 
medications, and the increase in blood-brain barrier permeability particularly in acute 
physical illness 3. Older people are also at relatively high risk of being exposed to 
medications with anticholinergic effects, due to their high medical morbidity, their 
frequent use of prescribed and over-the-counter medications; those that take such 
medication are more likely to be cognitively impaired than those who do not 4. In the 
US it is estimated that 20-50% of patients with dementia, take at least one medication 
with some anticholinergic activities 5,6,7. 
 Cholinergic mechanisms have been implicated in the aetiology of delirium, to which 
older people are also vulnerable 8. People with Alzheimer’s Disease (AD) may be at 
particular risk of cognitive deterioration secondary to medications with 
anticholinergic effects because of their marked reduction in the functioning of  their 
central cholinergic pathways 9.   
The aim of this study was to examine whether cholinergic burden was associated with 
the magnitude of current cognitive impairment or predicted the rate of future 
cognitive deterioration in a cohort of people with AD participating in a naturalistic 
follow-up study. 
 
METHODS  
The study is part of a larger longitudinal cohort study of 224 participants with AD, the 
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London and South East Region AD (LASER-AD) study10.  People with AD and their 
carers were approached through a variety of sources: their local community mental 
health team, dementia specialist nurses, the voluntary sector (including the 
Alzheimer’s Society), memory clinics, nursing and residential homes, day hospitals 
and inpatient units. Some of the participants had not received a diagnosis of AD, but 
the doctor in the research team screened and confirmed the diagnosis in all the 
participants. The participants were prospectively recruited purposively in order to be a 
sample of people with AD similar to that in the general population in terms of severity 
of cognitive impairment, gender and living situation 11.  
The inclusion criteria were a standardised diagnosis of dementia 12 and fulfillment of 
criteria for possible or probable AD13, being aged over  55 years, living in either 
North London or Essex and being in contact with a family or statutory carer for at 
least four hours a week.  The interviews were conducted by trained, experienced 
health professionals and comprised socio-demographic details, a medical and 
psychiatric history and physical examination. Follow-up interviews were undertaken 
at 6 and 18 months. Cognitive function was measured at baseline and at follow-up 
using the following: (1) Mini-Mental State Exam (MMSE) 14  Potential score ranges 
from 0-30. (2) The Severe Impairment Battery (SIB) 15  The SIB assesses the 
cognitive abilities of more impaired patients with dementia. Potential scores range 
from 0 to 100 16,17 and (3) the Alzheimer’s Disease Assessment Battery, Cognitive 
subsection (ADAS-COG)18. The range is 0–75; higher scores indicate greater 
dysfunction. 
The researcher documented all the prescribed and over the counter drugs that each 
patient was taking at baseline. 
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For the purposes of this study, each LASER-AD participant’s ‘anticholinergic burden’ 
was calculated using the Anticholinergic Burden Scale (ABS) which we had 
previously developed 19,20,21.  The scale was developed through a systematic review of 
the literature to identify drugs with documented anticholinergic activity. Content 
validity was tested by presenting the list to an expert interdisciplinary panel that 
included geriatricians, pharmacists, old age psychiatrists, general physicians, 
specialist geriatric nurses, and aging brain researchers. Using their clinical and basic 
science expertise as well as the documentation provided, a consensus approach was 
used to classify the potential anticholinergic effects of individual drugs into four 
groups (none = 0; mild = 1; moderate = 2; severe = 3). An individual’s 
‘anticholinergic burden’ (ABS) can then be calculated by summing the scores for all 
the drugs that patient is taking. Its predictive validity of cognitive decline has been 
shown in two large samples of community-dwelling older people21,22,23. The ABS 
captures individual medication therefore to facilitate medication coding three 
investigators (CF,IM, DS) reviewed all medication content to code medications not 
covered, such as mixed formulations, Finally, three authors (CF, CK, IM) reviewed 
the individual patient medication lists collected at baseline to calculate the total ABS 
in each patient. Any disagreement was resolved by discussion until a consensus was 
obtained.  
 
Analysis 
 
We report descriptive statistics and as appropriate parametric or non-parametric 
correlation coefficients of ABS load with cognitive outcome and possible 
confounders. To correct for multiple testing, we considered an alpha value of  p <0.01 
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as significant and to explore the impact of ABS load on cognition at 6 and 18 months, 
we conducted an analysis of covariance with a dichotomous fixed factor, ABS > 0 and 
ABS = 0, with the ADAS-COG, MMSE and SIB at 6 and 18 months as the dependent 
variables, controlling for confounding covariates; baseline measures of cognition, age, 
gender and whether patients where receiving a cholinesterase inhibitor. Where 
necessary to meet the assumptions of analysis of covariance, outcomes were 
transformed with the results being transformed back for ease of interpretation. 
 
Power calculation 
Our sample size was sufficient to detect a clinically significant correlation 
(conventionally taken as 0.4 or greater) at the 0.001% level 
(http://department.obg.cuhk.edu.hk/index.asp?scr=1280).  
 
Results  
 
We interviewed 224 people (160 women; 71.4%) with AD at baseline. 151 were 
living at home and the remainder in institutional care. Their mean age was 81.0 years 
(SD 7.4 [range 55-98]). At 18 months, 167 (74.6%) people completed follow-up. A 
total of 48 (21.4%) had died. Eight (3.6%) refused to take part. One (0.4%) had moved 
too far away to be interviewed. Participants who died were older (mean: 84.4 [SD 6.5] 
vs 80.20 [SD 7.5] p < 0.001) and more cognitively impaired on MMSE (mean: 11.0 
[SD 8.3] vs 15.68, [SD 7.4] p < 0.001), and more likely to be living in 24-hour care 
accommodation (24 [50.0%] vs 48 [28.7%], p < 0.01). Participants, who refused were 
not significantly different demographically from the rest of the population. The 
description of the baseline population is shown in table 1. At baseline those with a 
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greater ABS has a lower level of cognition as measured by the SIB and MMSE. 
The average number of medications was 3.6 (SD 2.4) and the mean anticholinergic 
load was 1.1 (SD 1.4) with a range of 0-7.  At baseline 47% of participants were on 
cholinesterase inhibitors; at 18 months this had risen to 56%. There was no effect of 
use of cholinesterase inhibitors on the results. 
The results confirmed the expected correlation between total number of drugs taken 
and anticholinergic load (rho=0.44 p<0.01). There were no significant correlations 
between changes in cognitive score and the total number of medications taken (Table 
2).  
There was no significant correlation between ABS score and cognition using any of 
the three measures (ADAS-COG, MMSE and SIB) at baseline, 6 months or 18 
months. ABS baseline scores were not normally distributed, with 101 participants 
having an ABS score of 0, 58 participants a score of 1 and 63 participants a score > 1. 
In order to have large and similar numbers of people in both groups, we compared 
baseline cognitive scores between participants with ABS scores of 0 and those with 
ABS scores of 1 or more. For participants with information available at both time-
points, we also compared cognitive scores at 6 and 18 months, adjusting for baseline 
cognitive scores, use of cholinesterase inhibitors, age and gender, between the groups 
with baseline ABS score of 0 and the group with a score of  ≥1 . These results are 
summarised in Table 3. There was no significant difference between the groups on 
any of the cognitive measures.  
There was no correlation between baseline anticholinergic load (as a continuous 
variable) and change in MMSE (rho=0.03 NS), change in ADAS-COG (rho=0.09 NS) 
or change in SIB (rho=0.08 NS) at 18 months.  
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Discussion 
This is the largest study of an Alzheimer naturalistic cohort to consider the effect of 
cholinergic burden on cognition of people with AD. Its strengths include that it had 
more than adequate power and used three different instruments to measure cognition 
to ensure there was no ceiling or floor limitation in measurement and to traingulate 
the findings.  There was no effect on cognition, either at baseline or 18 months later. 
The commonest group of medications in this sample with anticholinergic effects were 
psychotropics. The failure to show any effect contrasts with other studies which have 
looked at non-dementia samples where an effect has been found using the same 
assessment tool 20,21 . In a previous paper from the LASER study, we have however 
reported the absence of correlation between exposure to (and dosage of) atypical 
psychotropic medication and cognitive decline when neuropsychiatric symptoms were 
taken into account 24.  
 
The lack of an effect of ABS in this study (in contrast to the positive findings in a 
smaller but similar study25 ) may be because of the decreased sensitivity of patients 
with more advanced cognitive impairment or because those on established 
anticholinergic medication do not deteriorate on cognition more quickly. This is 
supported by the group with a clinically meaningful ABS at baseline having lower 
cognition sores as measured by the MMSE and SIB at baseline. Alternatively, 
therapeutically the result could be interpreted as suggesting that medications with 
anticholinergic effects may not be as damaging to cognition as first thought in 
established dementia.. 
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There are a number of limitations of this study which may also have contributed to the 
negative results. The average anticholinergic load score  and number of medications 
patients were taking were low. However, this and the number of medications with 
anticholinergic effects were in line with other studies in different population which 
showed an association20,21. The duration of follow up of 18 months may be seen as a 
limitation, but this is long enough to see a clinically relevant effect in this population. 
We only examined baseline medication and the effect of compliance was not 
measured. We may have missed the stage of critical importance for medications with 
anticholinergic effect beyond which damage to the cholinergic system had already 
occurred and may have passed a critical threshold. The ABS scale may lack 
sensitivity to detect an association.  Additionally about half the people in our study 
were taking cholinesterase inhibitors which may have masked the cognitive effects of 
co-prescribed medications with anticholinergic effects. However when this was 
analyzed there was no effect but this may have been limited by the small sample size. 
We did not have complete data on dosages of anticholinergic drugs and the duration 
that individuals were exposed to them.  
The ABS Scale has recently been validated as a predictor of cognitive impairment in 
two large samples of community-dwelling older people of patients without dementia 
20,21,22. Ideally it should also be validated against a biomarker ‘gold standard’.  
Reviews of the relevant literature concluded that radio-receptor assay may provide a 
reliable, reproducible and potent predictor of the impact of these medications on 
cognition26,27 .  Such an approach would need to consider dose of medication and the 
effect of more than one drug with anticholinergic effects. Radio-ligand assays rely on 
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serum samples and use rodent tissue. However this may not represent in vivo effects 
as the blood brain barrier permeability can alter and the muscarinic receptor blockade 
on serum may not be representative of brain tissue effects19,20,28,29.  This approach 
should be incorporated into a future study in order to validate non-laboratory 
assessment tools.  
The scale we used is broad and covers all representative medication; however there 
may be particular types of medication with anticholinergic effects which have a 
particularly potent effect.  Such specific effects might have been lost with the present 
scale. A further area of further development of the scale is that it does not take into 
account the effect of dose of medication, for example, a patient prescribed 5mg of 
procyclidine daily will have the same burden score as a patient prescribed 30mg of 
procyclidine daily. The tool should be further developed to take into account dosage. 
We conclude that, in this study of people with Alzheimer’s disease, that taking 
possibly a low dose of one medication with a low degree of anticholinergic activity 
(an ABS score of 1) does not predict more impaired cognition or a more rapid 
cognitive decline over the next 6 or 18 months.  Furthers studies are needed which 
include people who are cognitively intact as well as those with dementia and use an 
instrument which is validated against a biomarker. 
 
Acknowledgement: We are grateful to the patients, their families and staff who took 
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Table 1: Baseline description of the sample 
 
 ABS = 0 ABS>=1 p-value 
Mean number of drugs 
(SE) 
 
% Male 
 
Mean age (SE) 
 
Mean MMSE Score (SE) 
 
Mean ADASCOG (SE) 
 
Mean SIBTOT (SE) 
 
% Taking CHEI 
 
2.53 (0.18) 
 
32 
 
80.48 (0.69) 
 
16.20 (0.81) 
 
34.42 (1.92) 
 
82.52 (2.70) 
 
59 
 
4.58 (0.21) 
 
26 
 
81.47 (0.71) 
 
13.50 (0.75) 
 
40.04 (1.91) 
 
30.94 (2.80) 
 
47 
 
<0.001 
 
0.22 
 
0.32 
 
0.01 
 
0.04 
 
0.07 
 
0.06 
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Table 2: Correlations between change in cognitive score and total number of 
medications 
 
 Pearson 
Correlation with 
total number of 
drugs taken 
Sig (2-tailed) N 
Change in 
MMSE BL to 
6months 
0.14 0.054 163 
Change in 
MMSE BL to 18 
months 
0.06 0.47 163 
Change in SIB 
BL to 6mths 
0.04 0.61 195 
Change in SIB 
BL to 18 months 
0.01 0.94 152 
Change in 
ADAS-COG BL 
to 6month 
0.06 0.36 224 
Change in 
ADAS-COG BL 
to 18 months 
0.03 0.67 156 
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Table 3: Baseline, month 6  and 18 and adjusted mean differences for cognitive 
measures  categorized by ABS score 0 or 1 or more. 
 
Cognitive 
Measure 
Baseline mean 
    (95% CI n) 
Month 6 mean 
     (95% CI n) 
Month 6 Mean 
difference 
(95% CI) 
 
Month 6  
p-value 
 
Month 18 
mean 
     (95% CI n) 
Month 18 
Mean 
difference
(95% CI) 
 
ADAS-COG 
ABS=0 
 
 
 
 
ABS=/>1 
 
29.67  
(26.58; 33.12) 
       
         n=224 
 
34.47  
(31.19; 38.47) 
 
 
31.37  
(29.66; 33.18) 
         
        n=156 
 
32.96  
(31.25; 34.78) 
 
 
 
 
       
        -1.59  
(-1.14;1.03) 
 
 
 
 
 
 
       
        0.22 
 
33.92  
(31.50; 36.56) 
 
n=156 
 
35.41  
(32.88; 38.17) 
 
 
 
 
 
 
-1.49 
(-1.96; 1.06)
 
 
 
MMSE 
ABS =/> 0 
 
 
 
 
ABS =/> 1 
 
       
         16.20  
    (14.60;17.80) 
 
n=224 
 
13.50  
(12.02; 14.99) 
 
 
14.52  
(13.79; 15.24) 
          
       n=163 
  
13.99  
(13.32; 14.67) 
 
        
 
        
          
         0.53  
   (-0.47;1.53) 
 
 
 
      
     
       0.26 
 
       13.08 
(11.98; 14.16) 
 
n=163 
 
12.39   
(11.34; 13.44) 
 
        
 
          
         
        0.69 
(-0.84; 2.21)
 
 
SIB 
ABS  =   0 
 
 
 
 
ABS  =/> 1 
 
 
82.53  
(77.16; 87.89) 
 
n=224 
 
75.41  
(69.86; 80.96) 
 
 
77.68  
(74.75; 80.62) 
 
n=195 
 
75.94  
(73.22; 78.65) 
 
       
 
 
 
1.75  
(-2.28; 5.77) 
 
 
 
   
       0.39 
 
74.75  
(70.11; 79.38) 
 
n=152 
 
68.51  
(64.02; 73.00) 
 
       
 
        
         
        6.23  
(-0.26; 12.73
 
 
 
 
Covariates included in the model are baseline values, age and gender 
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